AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33895716 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of existential distress at five points (baseline, 3, 6, 9, and 12 months).
Number of subjects: 1000
Study 33895716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear and logistic regression analyses to calculate the predictive impact of existential distress on end-of-life outcomes.
Number of subjects: 1000
Study 33895716 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mixture models to analyze longitudinal trajectories of existential distress.
Number of subjects: 1000
Study 33895806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 33895806 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 33895809 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic classification (including transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction)
Number of subjects: 1229
Study 33895809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk genotypes (Ph-like, KMT2A-AFF1, low-hypodiploid/near-haploid, BCL2/MYC-rearranged)
Number of subjects: 1229
Study 33895809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk genotypes (PAX5alt, ZNF384/-like, MEF2D-rearranged)
Number of subjects: 1229
Study 33895809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk (DUX4-rearranged, ETV6-RUNX1/-like, TCF3-PBX1, PAX5 P80R, high-hyperdiploid)
Number of subjects: 1229
Study 33895809 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1 alterations and TP53 mutations
Number of subjects: 1229
Study 33895822 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep condition
Number of subjects: 16
Study 33895822 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation condition
Number of subjects: 16
Study 33895874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paromomycin and metronidazole
Number of subjects: 92
Study 33896710 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparametric magnetic resonance imaging as a screening tool for prostate cancer
Number of subjects: 0
Study 33896710 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33897480 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Adaptive Tests (CAT) of Depression and Suicidal Ideation
Number of subjects: 20
Study 33897480 — intervention group
Group type: COMPARATOR
Intervention: Traditional ratings (Hamilton Depression Rating Scale, Beck Depression Inventory, Beck Scale for Suicidal Ideation)
Number of subjects: 20
Study 33897536 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal bonding measures; specific intervention details not available
Number of subjects: 0
Study 33897579 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention for motor and cognitive rehabilitation, details on dosage and duration not available.
Number of subjects: 0
Study 33897579 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 33897593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Number of subjects: 0
Study 33897615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Number of subjects: 94
Study 33897775 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural oscillations measured 2 hours before surgery (specifically spectral power density of resting-state beta and gamma band oscillations at the frontocentral region)
Number of subjects: 0
Study 33897775 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques predicting acute postoperative pain based on neural oscillations
Number of subjects: 0
Study 33898065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant agents (OACs), including vitamin K antagonists (VKAs) and direct OACs (DOACs)
Number of subjects: 2000
Study 33898065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant agents (OACs)
Number of subjects: 2000
Study 33898536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy
Number of subjects: 0
Study 33898536 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33898953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 7829
Study 33898953 — intervention group
Group type: EXPERIMENTAL
Intervention: levonorgestrel (LNG) implant
Number of subjects: 7829
Study 33898953 — intervention group
Group type: COMPARATOR
Intervention: copper intrauterine device (IUD)
Number of subjects: 7829
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 0.3 mg
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 6 mg
Number of subjects: 238
Study 33898959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg (PSC)
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg (PSC)
Number of subjects: 238
Study 33898959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PSC)
Number of subjects: 238
Study 33898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin
Number of subjects: 238
Study 33898960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carb High-Fat diet (LCHF)
Number of subjects: 74
Study 33898960 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 diet
Number of subjects: 74
Study 33898960 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 74
Study 33899008 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program (4-week videoconference-based group intervention, 3 sessions per week)
Number of subjects: 172
Study 33899008 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Number of subjects: 172
Study 33899008 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 172
Study 33899152 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1568
Study 33899152 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1568
Study 33899152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1568
Study 33899504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for murmur detection
Number of subjects: 962
Study 33899504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for murmur detection (omitting grade 1 murmurs)
Number of subjects: 962
Study 33899504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for detecting aortic stenosis
Number of subjects: 962
Study 33899504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for detecting mitral regurgitation
Number of subjects: 962
Study 33899755 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging arboviruses
Number of subjects: 0
Study 33899755 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroinvasive arboviruses
Number of subjects: 0
Study 33899978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 250
Study 33899978 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 250
Study 33900000 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-enema
Number of subjects: 16
Study 33900000 — intervention group
Group type: COMPARATOR
Intervention: WSCE
Number of subjects: 16
Study 33900000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience
Number of subjects: 16
Study 33900000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy reversal
Number of subjects: 16
Study 33900099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Parenting Scale (MAPS)
Number of subjects: 1790
Study 33900278 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-like protein 3 inhibitors
Number of subjects: 0
Study 33900278 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33900485 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 20
Study 33900485 — intervention group
Group type: COMPARATOR
Intervention: Healthy young men (control group)
Number of subjects: 20
Study 33901053 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 3103
Study 33901053 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone (Americas-based sample)
Number of subjects: 3103
Study 33901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue specificity-aware TWAS (TSA-TWAS)
Number of subjects: 0
Study 33901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-tissue TWAS (UTMOST)
Number of subjects: 0
Study 33901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tissue TWAS (PrediXcan)
Number of subjects: 0
Study 33901280 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism (restoration of euthyroidism)
Number of subjects: 51
Study 33901438 — intervention group
Group type: COMPARATOR
Intervention: Having 2-3 chronic conditions vs 0-1
Number of subjects: 2438
Study 33901438 — intervention group
Group type: COMPARATOR
Intervention: Having ≥4 chronic conditions vs 0-1
Number of subjects: 2438
Study 33901438 — intervention group
Group type: COMPARATOR
Intervention: Presence of 2-3 chronic conditions
Number of subjects: 2438
Study 33901438 — intervention group
Group type: COMPARATOR
Intervention: Presence of ≥4 chronic conditions
Number of subjects: 2438
Study 33901438 — intervention group
Group type: COMPARATOR
Intervention: Triad of arthritis, depression, and anxiety
Number of subjects: 2438
Study 33901551 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at clinically administered doses using the Total Intravenous Anesthesia (TIVA/TCI) technique
Number of subjects: 27
Study 33901660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail ultrasonography (NUSG)
Number of subjects: 90
Study 33901660 — intervention group
Group type: EXPERIMENTAL
Intervention: NUSG Index (NUSGI)
Number of subjects: 90
Study 33901660 — intervention group
Group type: COMPARATOR
Intervention: NUSG
Number of subjects: 90
Study 33902087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive music during ketamine infusion
Number of subjects: 2
Study 33902087 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion without music
Number of subjects: 2
Study 33902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching intervention
Number of subjects: 54
Study 33902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior in the afternoon
Number of subjects: 54
Study 33902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior in the evening
Number of subjects: 54
Study 33902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 54
Study 33902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Daily Stress
Number of subjects: 0
Study 33902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Food Consumption
Number of subjects: 0
Study 33902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered Eating
Number of subjects: 0
Study 33902450 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PpO2 (> 250 mmHg)
Number of subjects: 376
Study 33902450 — intervention group
Group type: COMPARATOR
Intervention: Lower PpO2 (≤ 250 mmHg)
Number of subjects: 376
Study 33902478 — intervention group
Group type: EXPERIMENTAL
Intervention: KCD score ≥ 20 years (KCD20)
Number of subjects: 0
Study 33902478 — intervention group
Group type: COMPARATOR
Intervention: KCD20, eGFRstep, or eGFR < 60 ml/min/1.73 m²
Number of subjects: 0
Study 33902478 — intervention group
Group type: EXPERIMENTAL
Intervention: KCD20 or eGFR < 60 ml/min/1.73 m²
Number of subjects: 0
Study 33902478 — intervention group
Group type: EXPERIMENTAL
Intervention: KCD20
Number of subjects: 0
Study 33902478 — intervention group
Group type: EXPERIMENTAL
Intervention: KCD score
Number of subjects: 0
Study 33902556 — intervention group
Group type: COMPARATOR
Intervention: Higher plasma mitochondrial DNA (p-mtDNA) levels in participants with mild or moderate COPD compared to smokers without airflow obstruction and participants with severe COPD.
Number of subjects: 700
Study 33902556 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma mitochondrial DNA (p-mtDNA) levels in male participants with severe COPD.
Number of subjects: 700
Study 33902556 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline increased p-mtDNA levels in females with severe COPD.
Number of subjects: 700
Study 33902599 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 17 months age-group
Number of subjects: 14329
Study 33903092 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive APLA serology in COVID-19 patients
Number of subjects: 22
Study 33903092 — intervention group
Group type: COMPARATOR
Intervention: Positive APLA serology in non-COVID-19 patients
Number of subjects: 22
Study 33903114 — intervention group
Group type: EXPERIMENTAL
Intervention: External popPK model of TMP
Number of subjects: 0
Study 33903114 — intervention group
Group type: EXPERIMENTAL
Intervention: External popPK model of SMX
Number of subjects: 0
Study 33903114 — intervention group
Group type: COMPARATOR
Intervention: POPS TMP model
Number of subjects: 0
Study 33903114 — intervention group
Group type: COMPARATOR
Intervention: POPS SMX model
Number of subjects: 0
Study 33903148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0
Study 33903148 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet
Number of subjects: 0
Study 33903148 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-deficient high-fat diet
Number of subjects: 0
Study 33903148 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet supplemented with fructose and glucose
Number of subjects: 0
Study 33903148 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 33903148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate (PPARα agonist)
Number of subjects: 0
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting intracranial stenosis ≥50% and carotid mean wall thickness (MWT) ≥1 mm
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcification
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-rich necrotic core (LRNC)
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting intracranial artery stenosis ≥50% and carotid MWT ≥1 mm
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting intracranial stenosis ≥50% with carotid MWT ≥1 mm (after adjustment)
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcification (after adjustment)
Number of subjects: 351
Study 33903178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-rich necrotic core (LRNC) (after adjustment)
Number of subjects: 351
Study 33903179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (r-tPA), median dose 0.88 (IQR 0.78-0.90) mg/kg
Number of subjects: 3810
Study 33903179 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (UK), median dose 1.71 (1.43-2.00)×10
Number of subjects: 3810
Study 33903179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both r-tPA and UK
Number of subjects: 3810
Study 33903255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 4422
Study 33903255 — intervention group
Group type: COMPARATOR
Intervention: Lower education
Number of subjects: 4422
Study 33904646 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane chemotherapy (docetaxel or cabazitaxel)
Number of subjects: 0
Study 33904819 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based computerized cognitive training (CCT) program, 10-week duration, 2-hour instructor-led group classes twice a week.
Number of subjects: 94
Study 33904819 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 94
Study 33904821 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported computerized history taking (CHT) on a tablet
Number of subjects: 500
Study 33904895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 33904996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns including 'starchy veggies, meats and alcohol pattern'
Number of subjects: 1255
Study 33904996 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing intake of dietary proteins and total fats
Number of subjects: 1255
Study 33904996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary total fats
Number of subjects: 1255
Study 33904996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary saturated fats, omega-3 fats, and fiber
Number of subjects: 1255
Study 33905010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye leak test (DLT)
Number of subjects: 40
Study 33905010 — intervention group
Group type: COMPARATOR
Intervention: Air leak test (ALT)
Number of subjects: 40
Study 33905010 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture reinforcement of the anastomosis
Number of subjects: 40
Study 33905264 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide (PTCy) with myeloablative or reduced-intensity conditioning
Number of subjects: 80
Study 33905264 — intervention group
Group type: COMPARATOR
Intervention: Post-transplant cyclophosphamide (PTCy)
Number of subjects: 80
Study 33905373 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of β cell mass (50% mass reduction)
Number of subjects: 0
Study 33905373 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (post-NGT)
Number of subjects: 0
Study 33905373 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance (post-IGT)
Number of subjects: 0
Study 33905373 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus (post-DM)
Number of subjects: 0
Study 33905540 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapies that reduce gastric acidity
Number of subjects: 273
Study 33905540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 analogue misoprostol
Number of subjects: 273
Study 33905540 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 273
Study 33905544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 33905544 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 33906372 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) summary score
Number of subjects: 23291
Study 33906372 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ-12 summary score
Number of subjects: 23291
Study 33906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical genetic testing for cardiomyopathy
Number of subjects: 152
Study 33906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history and hypertrophic cardiomyopathy subtype
Number of subjects: 152
Study 33906377 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt (HS) treatment
Number of subjects: 0
Study 33906377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological uncoupling of the electron transport chain under normal salt
Number of subjects: 0
Study 33906420 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin, Free Triiodothyronine, and Free Thyroxine measurements
Number of subjects: 0
Study 33906916 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-Only iLet Bionic Pancreas
Number of subjects: 0
Study 33906916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal iLet Using Dasiglucagon
Number of subjects: 0
Study 33906957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic excursion velocity measured with dTDI at the end of SBT
Number of subjects: 100
Study 33907136 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acupressure therapy at acupoints TE17 (Yifeng), TE21 (Ermen), SI19 (Tinggong), and GB2 (Tinghui)
Number of subjects: 152
Study 33907136 — intervention group
Group type: COMPARATOR
Intervention: Conventional Valsalva and Toynbee maneuvers
Number of subjects: 152
Study 33907423 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessorized pre-filled syringe (APFS)
Number of subjects: 216
Study 33907423 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 216
Study 33907423 — intervention group
Group type: COMPARATOR
Intervention: Both APFS and AI
Number of subjects: 216
Study 33907423 — intervention group
Group type: EXPERIMENTAL
Intervention: APFS
Number of subjects: 216
Study 33907423 — intervention group
Group type: EXPERIMENTAL
Intervention: AI
Number of subjects: 216
Study 33907455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group (0.5% ropivacaine plus 0.033% dexamethasone)
Number of subjects: 140
Study 33907455 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5% ropivacaine alone)
Number of subjects: 140
Study 33907455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 140
Study 33907462 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprainguinal fascia iliaca block (FIB)
Number of subjects: 36
Study 33907462 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (QLB)
Number of subjects: 36
Study 33908631 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and antibiotics
Number of subjects: 21
Study 33908631 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 21
Study 33909232 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg once weekly in combination with intravenous topotecan
Number of subjects: 14
Study 33909232 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg
Number of subjects: 14
Study 33909232 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Number of subjects: 14